Non-Hodgkins Lymphoma

This is a class of lymphomas which is really a whole family (about 35 in total) of different cancers of lymphocytes - non-Hodgkins lymphoma is divided into 2 major groups : ones affecting the B-lymphocytes and the ones affecting T-lymphocytes. Non-hodgkins lymphoma is the most common kind of cancer of the lymphatic system.

There are several factors that can predispose people to getting non-Hodkins lymphoma, they are :

Return to lymphoma symptoms

Read about Hodgkins Lymphoma

Non-Hodgkins Lymphoma

Lymphoma / Leukemia News From Medical News Today
Latest Lymphoma / Leukemia News From Medical News Today.

Vion Pharmaceuticals Enters Into Agreement With HOVON To Conduct A Phase III Clinical Trial Of Cloretazine(R)
VION PHARMACEUTICALS, INC. (Pink Sheets: VION) announced that it had entered into an agreement with the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (the "HOVON") to conduct a clinical trial of laromustine (Cloretazine(R) (VNP40101M)) with standard remission-induction therapy in patients aged 18-65 with previously untreated acute myelogenous leukemia (AML) and high-risk myelodysplasia (MDS).
Asuragen, Inc. Launches Signature® NPM1 Mutations (RUO): A Rapid Multiplex Assay For The Detection Of NPM1 Mutations
Asuragen, Inc. announced the launch of Signature® NPM1 Mutations (RUO), a multiplex reverse transcription PCR (RT-PCR) assay that enables the detection of NPM1 mutations. Asuragen's Signature® NPM1 Mutations is a sensitive molecular assay for the combined detection of mutations A, B and D in exon 12 of the nucleophosmin (NPM1) gene. Asuragen is one of two exclusive licensees to NPM1.
Plerixafor Treatment Improves Mobilization Of Cells In Donors During Bone Marrow Stem Cell Collection Procedures
In a study of 25 bone marrow donors, treatment with plerixafor, an antagonist able to disrupt a critical pathway associated with stem cell mobilization, was shown to mobilize cells faster than treatment with granular colony-stimulating factor (G-CSF), the current standard method used to collect bone marrow stem cells from healthy donors.
The Multiple Myeloma Research Consortium Announces Initiation Of First Four-Drug Combination Study To Treat Newly Diagnosed Multiple Myeloma Patients
The Multiple Myeloma Research Consortium (MMRC) announced the initiation of a four-drug combination study with REVLIMID® (lenalidomide), VELCADE® (bortezomib) for Injection, DOXIL® (doxorubicin HCl liposome injection) and dexamethasone for the treatment of multiple myeloma in patients who are previously untreated.
Inhibitors Of The Molecule PI3K Throw One Form Of Leukemia A CurveB-ALL
 Some cases of a form of leukemia known as pre-B cell acute lymphoblastic leukemia (pre-B-ALL) are caused by a genetic event that leads to the generation of a rogue chromosome known as the Philadelphia (Ph) chomosome, and individuals with Ph+ pre-B-ALL tend to have a poor outlook. As current treatments for Ph+ pre-B-ALL are not very effective, researchers are looking for new drugs to combat this disease.